A Review of Prescription Drug Affordability Boards
Journal of Healthcare Finance · 15.09.2026 · 16
DOI: 10.68415/x1n3ts77 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Healthcare Finance, online erschienen am 15.09.2026. Verfasst von Kwame Kissi-Twum und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
In the United States, rising prescription drug costs are a growing concern for policymakers. In response, several states have established Prescription Drug Affordability Boards (PDABs) to evaluate high-cost drugs, assess their affordability for patients and payers, and, where authorized, establish upper payment limits (UPLs).
Objectives
To characterize statutory and governance differences across PDABs, examine how each state defines and operationalizes “affordability” in policy and law, and synthesize quantitative data on drugs selected for affordability review or UPL consideration.
Methods
We identified PBABs that were active as of October 24, 2025. We included state entities that had the authority to conduct drug affordability reviews or use strategies such as UPLs. We excluded entities that functioned exclusively as price transparency or data-reporting commissions. For each state, we reviewed enabling statutes and publicly released data files. We extracted data on statutory design, governance structure, affordability definitions, and drugs identified for affordability review, and summarized cross-state similarities and differences.
Results
We identified 5 PDABs in Maryland, Colorado, Oregon, Washington, and Minnesota. Across states, boards required expertise in clinical medicine or healthcare economics. Drugs were identified for affordability reviews based on wholesale acquisition costs (WAC) thresholds, such as WAC increases of $300 or more or 200% or more in the prior 12 months, or an annual WAC of $30,000 or more. For biosimilars, 4 PDABs considered whether they were launched at a 15% or 20% discount relative to the reference biologic. Drugs that progressed to full review were high-cost specialty therapies with high per-patient spending or rapid price growth, such as Enbrel.
Conclusion
PDABs share common structural features across states, but the extent of implementation differs. Although the long-term impact of PDABs on payer spending is uncertain, variation in transparency and prioritization across boards may influence how these policies evolve over time.
Zitieren
APA
Kissi-Twum, K., & II, T. J. M. (2026). A Review of Prescription Drug Affordability Boards. Journal of Healthcare Finance, 16. https://doi.org/10.68415/x1n3ts77
Vancouver
Kissi-Twum K, II TJM. A Review of Prescription Drug Affordability Boards. Journal of Healthcare Finance. 2026:16. doi:10.68415/x1n3ts77
BibTeX
@article{KissiTwum2026,
author = {Kissi-Twum, Kwame and II, T. Joseph Mattingly},
title = {A Review of Prescription Drug Affordability Boards},
journal = {Journal of Healthcare Finance},
year = {2026},
pages = {16},
doi = {10.68415/x1n3ts77}
}
EUVIMED